Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR31 adjuvant durvalumab after complete resection of non-small cell lung cancer
NL-OMON58995Phase 3Completed
- Sponsor
- NVALT
- Start
- Nov 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by NVALT. Primary endpoint: Disease-free survival. Started Nov 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58995.